Guth has Friedreich’s Ataxia and chose to raise money at Happy Place Nutrition for Friedreich’s Ataxia Research Alliance ...
When there are so few taxis in your regional city that you can actually use, it can be detrimental to your independence when ...
Cantor Fitzgerald initiated coverage of Lexeo Therapeutics (LXEO) with an Overweight rating and $19 price target Lead asset LX2006 is an ...
RBC Capital analyst Leonid Timashev upgraded Design Therapeutics (DSGN) to Outperform from Sector Perform with a price target of $13, up from $6.
The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback